NASDAQ:GERN Geron Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Geron Co. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.68 +0.01 (+0.30 %) (As of 09/25/2020 02:20 PM ET) Add Compare Share Today's Range$1.67Now: $1.69▼$1.7250-Day Range$1.60MA: $1.79▼$2.0552-Week Range$0.75Now: $1.69▼$2.40Volume46,437 shsAverage Volume2.65 million shsMarket Capitalization$523.14 millionP/E RatioN/ADividend YieldN/ABeta1.68 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It holds rights to imetelstat, a telomerase inhibitor in Phase 2/3 clinical trials, which inhibits the uncontrolled proliferation of malignant progenitor cells in hematologic myeloid malignancies to reduce dysfunctional blood cell production and enable recovery of normal blood cell production. The company was founded in 1990 and is headquartered in Menlo Park, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingGeron has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, Geron has a forecasted upside of 138.8% from its current price of $1.68.Amount of Analyst CoverageGeron has only been the subject of 2 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesGeron has received 446 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGeron has received 377 “underperform” votes. (Add your “underperform” vote.)Community SentimentGeron has received 54.19% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Geron and other stocks. Vote “Outperform” if you believe GERN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GERN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGeron does not currently pay a dividend.Dividend GrowthGeron does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Geron insiders have bought more of their company's stock than they have sold. Specifically, they have bought $30,173.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 7.70% of the stock of Geron is held by insiders.Percentage Held by Institutions50.36% of the stock of Geron is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Geron are expected to decrease in the coming year, from ($0.27) to ($0.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Geron is -4.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Geron is -4.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeron has a P/B Ratio of 2.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.04 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:GERN Previous Symbol CUSIP37416310 CIK886744 Webwww.geron.com Phone650-473-7700Debt Debt-to-Equity RatioN/A Current Ratio11.53 Quick Ratio11.53Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$460,000.00 Price / Sales1,137.25 Cash FlowN/A Price / Cash FlowN/A Book Value$0.68 per share Price / Book2.48Profitability EPS (Most Recent Fiscal Year)($0.36) Net Income$-68,550,000.00 Net Margins-19,251.64% Return on Equity-46.39% Return on Assets-40.90%Miscellaneous Employees45 Outstanding Shares310,467,000Market Cap$523.14 million Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $1.68 +0.01 (+0.30 %) (As of 09/25/2020 02:20 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive GERN News and Ratings via Email Sign-up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter. Geron (NASDAQ:GERN) Frequently Asked Questions How has Geron's stock price been impacted by Coronavirus? Geron's stock was trading at $1.03 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GERN stock has increased by 63.6% and is now trading at $1.6850. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Geron? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Geron. When is Geron's next earnings date? Geron is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Geron. How were Geron's earnings last quarter? Geron Co. (NASDAQ:GERN) announced its quarterly earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, hitting analysts' consensus estimates of ($0.06). The biopharmaceutical company had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.09 million. Geron had a negative net margin of 19,251.64% and a negative return on equity of 46.39%. View Geron's earnings history. What price target have analysts set for GERN? 6 equities research analysts have issued 12-month price targets for Geron's stock. Their forecasts range from $3.00 to $7.00. On average, they expect Geron's share price to reach $4.00 in the next year. This suggests a possible upside of 137.4% from the stock's current price. View analysts' price targets for Geron. Who are some of Geron's key competitors? Some companies that are related to Geron include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Immunomedics (IMMU), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX) and Repligen (RGEN). View all competitors. What other stocks do shareholders of Geron own? Based on aggregate information from My MarketBeat watchlists, some companies that other Geron investors own include Novavax (NVAX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Chesapeake Energy (CHKAQ), OrganiGram (OGI), Rigel Pharmaceuticals (RIGL), KushCo (KSHB) and SCYNEXIS (SCYX). Who are Geron's key executives? Geron's management team includes the following people: Dr. John A. Scarlett, CEO, Pres & Chairman (Age 69, Pay $1.15M)Ms. Olivia Kyusuk Bloom, Exec. VP of Fin., CFO & Treasurer (Age 51, Pay $687.17k)Dr. Andrew J. Grethlein, Exec. VP & COO (Age 56, Pay $705.69k)Ms. Melissa A. Kelly Behrs, Exec. VP & Chief Bus. Officer (Age 56, Pay $673.36k)Dr. Aleksandra Rizo M.D., Ph.D., Exec. VP & Chief Medical Officer (Age 45, Pay $968.2k) What is Geron's stock symbol? Geron trades on the NASDAQ under the ticker symbol "GERN." Who are Geron's major shareholders? Geron's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.60%), Great Point Partners LLC (7.57%), Perceptive Advisors LLC (4.34%), FMR LLC (6.14%), FMR LLC (4.02%) and Charles Schwab Investment Management Inc. (0.58%). Company insiders that own Geron stock include Elizabeth G O'farrell and Melissa Kelly Behrs. View institutional ownership trends for Geron. Which major investors are selling Geron stock? GERN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, FMR LLC, Bank of America Corp DE, UBS Group AG, Virtus ETF Advisers LLC, and Amalgamated Bank. View insider buying and selling activity for Geron. Which major investors are buying Geron stock? GERN stock was acquired by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Perceptive Advisors LLC, Vanguard Group Inc., Charles Schwab Investment Management Inc., Swiss National Bank, Nuveen Asset Management LLC, WINTON GROUP Ltd, and Bank of New York Mellon Corp. View insider buying and selling activity for Geron. How do I buy shares of Geron? Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Geron's stock price today? One share of GERN stock can currently be purchased for approximately $1.69. How big of a company is Geron? Geron has a market capitalization of $523.14 million and generates $460,000.00 in revenue each year. The biopharmaceutical company earns $-68,550,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Geron employs 45 workers across the globe. What is Geron's official website? The official website for Geron is www.geron.com. How can I contact Geron? Geron's mailing address is 919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected] This page was last updated on 9/25/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
